Trade and Investment Queensland’s Post

The Clinical Researcher of the Year – The Americas 2024 seeks to uncover talent among #clinicalresearchers across the Americas. This dynamic event encourages candidates to challenge themselves and one another as they showcase their passion and expertise in the field of clinical research. The awards feature various individual and team categories, including #ClinicalResearchCoordinator, #ClinicalTrialManager, Global Project Manager, and #CRAs (at three different levels) for individuals, and #GlobalProject Team, #GlobalPartnership Team, and Start-Up for teams. Additionally, a new category was introduced in 2024: #Decentralized Solutions Individual of the Year, aimed at Digital & Clinical Individuals to assess their understanding of the importance of decentralized solutions in #clinical research. For further information on entry requirements, please visit the website: Overview: Clinical Researcher of the Year - The Americas (pharmatimes.com) Categories: Categories - Clinical Researcher of the Year - The Americas (pharmatimes.com) #clinicalresearch #CROY #clinicalresearchcompetition #PharmaTimes #clinicaltrials #decentralizedsolutions

More exciting news from the RI Life Science Hub!

A project I worked on at No Patient Left Behind - the main takeaway I had is that drug pricing is precarious. America pays more than every other country per drug and keeps the pharma industry going. If everyone paid the non-American prices, the industry would collapse within a few decades. In my opinion, international reference pricing, where a country uses other countries' prices as reference points for their own, is overly simplistic and we should be very careful before applying it to patented drugs. Check out the carousel for more info and thanks to Edouard for helping put it all together!

Thanks to Moorhouse Consulting and Leo Koshutova for the invite to the Prix Galien UK forum hosted at the Science Museum recently. Timely topics with lively debate covered; ·      Patient focussed drug development –‘No decision for me without me’ ·      Introducing New Technologies: Optimising pathways to improve population health ·      Artificial intelligence to design new drugs ·      Innovation in R&D: The birth of breakthroughs ·      Data Driven Medicine: The NHS as a strategic partner in Life Sciences ·      Improving global health outcomes through clinical innovation Galien ensure meetings like these drive global debate on health and the importance of raising public awareness, allowing significant time for discussion between panels and audience.  In the UK as we navigate the near 24/7 election coverage, one welcome question sparked some thought provoking answers;  ‘What would the panel put on the manifesto for the [new] government?  . ‘there is much more to do on health inequality – uptake of innovation is low in those populations that are already chronically underserved’ ·      ‘there is an overwhelming need to focus on prevention among all stakeholders in healthcare as the system cannot sustain the more traditional treatment approaches’ ·      ‘Create an Innovation Adoption association – Innovation needs to be better coordinated with matching budgets’ ·      ‘We need to work to predict people’s individual health trajectories by using AI intelligently to help us manage the limited resources available’ This may have been a UK focussed meeting however these responses illustrate the challenges faced more globally. Michelle Warner

When we first started collaborating with Dr. Kenolisa Onwueme and Maryland’s Woodholme Gastroenterology Associates, they had both a keen interest in trials from their team and strong patient demand. However, building and scaling clinical trials is challenging, and many practices either fall short or struggle to achieve the revenue to sustain a program long-term. Success and scale requires significant resources, strong leadership, the right technology, and deep operational expertise in the space. Learn more about our work with Dr. Onwueme and the incredible research program at Woodholme. https://lnkd.in/ev4pyZfN

Manchester has ranked 14 of 41 European Life Sciences Clusters 🧬 In a recent report by JLL on the Life Sciences Industry Real Estate Outlook for 2024, Manchester was ranked 14th when comparing the growth of its life sciences sector against other successful European clusters. Some highlights include ⬇️ 📍Stating that Manchester is at the forefront of innovative treatments to improve patient care and an 'essential part of the UK's bid to be a 'Science Superpower' 🏢How our developments Citylabs and Manchester Science Park are amongst the major dedicated commercial schemes, offering flexible space for scaling companies, as well as Alderley Park and its large amount of life sciences dedicated supply. 👏Manchester has the largest life sciences corporate base in the UK, outside the Golden Triangle. When looking into the detailed sub-sector landscape, Manchester stands out for the number of “drug discovery & development services” companies with the likes of our customers Sai Life Sciences Ltd & Evotec You can read the full report here: https://bit.ly/3VSbGH1 And find out more about our supporting lab space for life science companies here ➡️ https://bit.ly/4cQAuGu

Join me with Paul Hinchliffe and Darren Matthews for a webinar discussing how Quotient Sciences and Charles River Laboratories integrated drug development programs can streamline your molecule's path through development.

We're excited to announce that we have been awarded almost £3.5m to establish a Commercial Research Delivery Centre (CRDC) - one of 20 being set up across the UK! ✨ The centre will enhance the speed and efficiency of commercial clinical research, providing more people in Sussex with access to cutting-edge treatments. Professor Martin Llewelyn, the Clinical Director of Research and Innovation at UHSussex, will be proudly leading the new CRDC. He said: “The CRDC funding award is fantastic news for patients and staff at University Hospitals Sussex and also for the wider population of Sussex. It will bring substantial commercial clinical research into our region. This will allow more people to access the latest treatment advances through clinical trials, help us develop research skills in the people who work in health and care and bring opportunities for job and economic growth across the region.” The new centre will leverage the strengths and expertise of UHSussex’s extensive NIHR portfolio, enhancing its role as a leader in clinical research and innovation. 💜

VCTC are attending the 14th Annual OCT Europe, 7 - 8 May ✨ Dan Henley, Helen Shaw (nee Kirkby), and Hugh McEnery will share insights on our innovative approach to virtual and decentralised trials and how we place the participant at the centre of their own trial experience, providing them with more control over how, when, and where they choose to participate. 💡 VCTC is the UK's first and only clinical trial site established specifically to address the burden that participants face when taking part in research studies. 🔬 Come and visit us at Booth 16 to find out how we can accelerate your research. 🚀 #octeurope #vctc #empoweringpatients #patientcentricity #decentralisedtrials #virtualtrials #clinicaltrialsite #clinicalresearch

⌛️ONLY ONE WEEK LEFT! 📢#RNs & #NPs: Join RNAO's Advanced Clinical Practice Fellowship (#ACPF) program info session and learn how the program can help you develop your skills, knowledge & expertise. 📢Register for the April 12 session to learn more: MyRNAO.ca/acpfinfosession